Carbon-14 labeled permethrin in ethanol solution was applied to the clipped skin of rats in vivo at doses of 2.25, 20, or 200 mu g/cm(2). As a reference compound, (14)C-labeled PBO in isopropanol solution was applied to rat skin in vivo at a dose of

100 mu g/cm(2). All applications were washed at 24 h postapplication, and rats were sacrificed either at 24 h for permethrin or 5 d for both compounds. The radiolabel recovered from carcass, urine including cage wash, and feces was summed to determine percent absorption. For the 24-h time point, at doses of 2.25, 20, and 200 mu Veliparib clinical trial g/cm(2) of permethrin, values of 22, 22, and 28%, respectively, were obtained for in vivo rat percutaneous absorption (n = 6 per dose). For the 5-d time point, at doses of 2.25, 20, and 200 mu g/cm(2) of permethrin, values of 38, 38, and 30%, respectively, were obtained for in vivo rat percutaneous absorption (n = 6 per dose). The 5-d percutaneous absorption of (14)C-PBO at 100 mu g/cm(2) was determined to be 42% (n = 6). Dose and test duration did not exert a statistically significant effect on percutaneous absorption of permethrin in the rat in vivo. For

in vitro absorption determination, (14)C-permethrin in ethanol solution was applied to freshly excised human skin in an in vitro https://www.selleckchem.com/products/E7080.html test system predictive of skin absorption selleck chemicals in humans. Twenty-four hours after application, the radiolabel recovered from dermis and receptor fluid was summed to determine percent absorption. At doses of approximately 2.25, 20, and 200 mu g/cm(2) permethrin, values of 1, 3, and 2%, respectively, were obtained for percutaneous absorption (n = 9 per dose). Excised human skin absorption of (14)C-PBO at 100 mu g/cm(2) was determined to be 7% (n = 9). Excised rat skin absorptions of permethrin

at 2.25, 20, and 200 mu g/cm(2) were found to be 20, 18, and 24%, respectively (n = 6 per dose), approximately 10-fold higher than human skin absorption. Excised rat skin absorption of PBO was also higher (35%) than the value obtained for human skin by a factor of about 5.”
“Delta opioid receptor (DOR) activation protects the adult mammalian brain during oxygen-glucose deprivation (OGD), but it is not known whether neonatal spinal motor circuits are also protected. Also, it is unclear whether the timing of spinal DOR activation relative to spinal OGD is important for neuroprotection. Thus, a split-bath in vitro neonatal rat brainstem/spinal cord preparation was used to record spontaneous respiratory motor output from cervical (C4-C5) and thoracic (T5-T6) ventral spinal roots while exposing only the spinal cord to OGD solution (0 mM glucose, bubbled with 95% N-2/5% CO2) or DOR agonist drugs (DADLE, DPDPE).